The impact of socioeconomic status on access to cancer clinical trials

Cancer clinical trials enable the development of novel agents for the potential benefit of cancer patients. Enrolment in a trial offers patients the chance of superior efficacy coupled to the risk of unanticipated toxicity. For trial results to be generalisable, the data need to be collected in pati...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 111; no. 9; pp. 1684 - 1687
Main Authors Sharrocks, K, Spicer, J, Camidge, D R, Papa, S
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 28.10.2014
Nature Publishing Group
Subjects
692/308/2779/109
692/699/67
706/689
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Clinical trials
Clinical Trials as Topic - economics
Drug Resistance
Education
Epidemiology
Health care access
Health Services Accessibility - economics
Healthcare Disparities
Humans
Life expectancy
Medical research
Medical sciences
Medical screening
Medicare
mini-review
Minireview
Molecular Medicine
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
National health insurance
Neoplasms - economics
Neoplasms - epidemiology
Neoplasms - psychology
Oncology
Prognosis
Socioeconomic Factors
Survival analysis
Tumors
Uninsured people
United Kingdom - epidemiology
United Kingdom > UK
United States > US
socioeconomics
cancer clinical trials
Cancerology
Socioeconomic status
Accessibility
Clinical trial
Economic aspect
Malignant tumor
Social aspect
Cancer
Online AccessGet full text

Cover

More Information
Summary:Cancer clinical trials enable the development of novel agents for the potential benefit of cancer patients. Enrolment in a trial offers patients the chance of superior efficacy coupled to the risk of unanticipated toxicity. For trial results to be generalisable, the data need to be collected in patients’ representative of the general cancer population. Socioeconomic deprivation is associated with poor cancer outcomes. In the developed world, the gap between the most and least deprived is widening. This mini-review explores the evidence regarding socioeconomics and access to cancer trials, highlighting the underrepresentation of deprived patients, and exploring reasons for this disparity.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2014.108